Fabrizio Galimberti, Ph.D. - Publications

Affiliations: 
2011 Pharmacology and Toxicology Dartmouth College, Hanover, NH, United States 
Area:
Molecular Biology, Oncology

20 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Hu S, Danilov AV, Godek K, Orr B, Tafe LJ, Rodriguez-Canales J, Behrens C, Mino B, Moran CA, Memoli VA, Mustachio LM, Galimberti F, Ravi S, DeCastro A, Lu Y, et al. CDK2 Inhibition Causes Anaphase Catastrophe in Lung Cancer through the Centrosomal Protein CP110. Cancer Research. 75: 2029-38. PMID 25808870 DOI: 10.1158/0008-5472.Can-14-1494  0.48
2014 Busch AM, Galimberti F, Nehls KE, Roengvoraphoj M, Sekula D, Li B, Guo Y, Direnzo J, Fiering SN, Spinella MJ, Robbins DJ, Memoli VA, Freemantle SJ, Dmitrovsky E. All-trans-retinoic acid antagonizes the Hedgehog pathway by inducing patched. Cancer Biology & Therapy. 15: 463-72. PMID 24496080 DOI: 10.4161/Cbt.27821  0.48
2014 Hu S, Danilov AV, Godek KM, Orr B, Tafe LJ, Memoli VA, Galimberti F, Ravi S, DeCastro AJ, Lu Y, Mustachio LM, Sekula DJ, Andrew AS, Freemantle SJ, Compton DA, et al. Abstract 4549: CDK2 inhibition causes anaphase catastrophe through the centrosomal protein CP110 Cancer Research. 74: 4549-4549. DOI: 10.1158/1538-7445.Am2014-4549  0.56
2013 Ma T, Galimberti F, Erkmen CP, Memoli V, Chinyengetere F, Sempere L, Beumer JH, Anyang BN, Nugent W, Johnstone D, Tsongalis GJ, Kurie JM, Li H, Direnzo J, Guo Y, et al. Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer. Molecular Cancer Therapeutics. 12: 1545-55. PMID 23686769 DOI: 10.1158/1535-7163.Mct-12-0933  0.56
2013 Rodriguez-Blanco J, Schilling NS, Tokhunts R, Giambelli C, Long J, Liang Fei D, Singh S, Black KE, Wang Z, Galimberti F, Bejarano PA, Elliot S, Glassberg MK, Nguyen DM, Lockwood WW, et al. The hedgehog processing pathway is required for NSCLC growth and survival. Oncogene. 32: 2335-45. PMID 22733134 DOI: 10.1038/Onc.2012.243  0.48
2012 Galimberti F, Busch AM, Chinyengetere F, Ma T, Sekula D, Memoli VA, Dragnev KH, Liu F, Johnson KC, Guo Y, Freemantle SJ, Andrew AS, Greninger P, Robbins DJ, Settleman J, et al. Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations. International Journal of Oncology. 41: 1751-61. PMID 22923130 DOI: 10.3892/Ijo.2012.1599  0.48
2012 Guo Y, Chinyengetere F, Dolinko AV, Lopez-Aguiar A, Lu Y, Galimberti F, Ma T, Feng Q, Sekula D, Freemantle SJ, Andrew AS, Memoli V, Dmitrovsky E. Evidence for the ubiquitin protease UBP43 as an antineoplastic target. Molecular Cancer Therapeutics. 11: 1968-77. PMID 22752428 DOI: 10.1158/1535-7163.Mct-12-0248  0.48
2011 Dragnev KH, Ma T, Galimberti F, Erkmen CP, Memoli V, Nugent W, Rigas JR, Johnstone D, Frandsen A, Simeone S, Czum J, Li H, DiRenzo J, Freemantle S, Dmitrovsky E. A window-of-opportunity trial of vorinostat (V) in patients with resectable non-small cell lung cancer (NSCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 7062. PMID 28020374 DOI: 10.1200/Jco.2011.29.15_Suppl.7062  0.56
2011 Dragnev KH, Ma T, Cyrus J, Galimberti F, Memoli V, Busch AM, Tsongalis GJ, Seltzer M, Johnstone D, Erkmen CP, Nugent W, Rigas JR, Liu X, Freemantle SJ, Kurie JM, et al. Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models. Cancer Prevention Research (Philadelphia, Pa.). 4: 818-28. PMID 21636548 DOI: 10.1158/1940-6207.Capr-10-0376  0.56
2011 Galimberti F, Thompson SL, Ravi S, Compton DA, Dmitrovsky E. Anaphase catastrophe is a target for cancer therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 1218-22. PMID 21288923 DOI: 10.1158/1078-0432.Ccr-10-1178  0.48
2011 Dragnev KH, Ma T, Cyrus J, Galimberti F, Memoli V, Busch AM, Tsongalis GJ, Seltzer MA, Johnstone D, Erkmen CP, Nugent W, Rigas JR, Liu X, Freemantle SJ, Kurie JM, et al. Abstract LB-412: Combining bexarotene with erlotinib in window of opportunity and phase II trials causes lung cancer responses independent of KRAS mutations Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-412  0.56
2011 Ma T, Galimberti F, Erkmen CP, Memoli V, Nugent W, Rigas J, Johnstone D, Li H, DiRenzo J, Freemantle S, Dragnev K, Dmitrovsky E. Abstract 342: Murine transgenic lung cancer models guide a proof of principle histone deacetylase inhibitor trial in lung cancer patients Cancer Research. 71: 342-342. DOI: 10.1158/1538-7445.Am2011-342  0.56
2011 Guo Y, Chinyengetere F, Dolinko AV, Lopez-Aguiar A, Galimberti F, Ma T, Feng Q, Andrew AS, Sekula D, Freemantle S, Memoli V, Dmitrovsky E. Abstract 1655: The ubiquitin protease UBP43 is a target for lung cancer therapy and prevention Cancer Research. 71: 1655-1655. DOI: 10.1158/1538-7445.Am2011-1655  0.56
2011 Galimberti F, Busch A, Chinyengetere F, Ma T, Sekula D, Memoli V, Dragnev K, Liu F, Andrew AS, Greninger P, Robbins D, Settleman J, Benes C, Dmitrovsky E. Abstract 1615: Gene expression profile predicts response to smoothened inhibitors in epithelial cancers Cancer Research. 71: 1615-1615. DOI: 10.1158/1538-7445.Am2011-1615  0.56
2010 Guo Y, Dolinko AV, Chinyengetere F, Stanton B, Bomberger JM, Demidenko E, Zhou DC, Gallagher R, Ma T, Galimberti F, Liu X, Sekula D, Freemantle S, Dmitrovsky E. Blockade of the ubiquitin protease UBP43 destabilizes transcription factor PML/RARα and inhibits the growth of acute promyelocytic leukemia. Cancer Research. 70: 9875-85. PMID 20935222 DOI: 10.1158/0008-5472.Can-10-1100  0.56
2010 Galimberti F, Thompson SL, Liu X, Li H, Memoli V, Green SR, DiRenzo J, Greninger P, Sharma SV, Settleman J, Compton DA, Dmitrovsky E. Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 109-20. PMID 20028770 DOI: 10.1158/1078-0432.Ccr-09-2151  0.48
2010 Guo Y, Dolinko A, Chinyengetere F, Bomberger J, Gallagher R, Ma T, Galimberti F, Liu X, Sekula D, Busch A, Freemantle S, Dmitrovsky E. Abstract 1594: Targeting UBP43 for repression destabilizes PML/RARα and inhibits acute promyelocytic leukemia growth Cancer Research. 70: 1594-1594. DOI: 10.1158/1538-7445.Am10-1594  0.56
2009 Liu X, Sempere LF, Galimberti F, Freemantle SJ, Black C, Dragnev KH, Yan M, Fiering S, Memoli V, Li H, Direnzo J, Korc M, Cole CN, Bak M, Kauppinen S, et al. Uncovering growth-Suppressive micro rNAs in lung cancer Clinical Cancer Research. 15: 1177-1183. PMID 19228723 DOI: 10.1158/1078-0432.Ccr-08-1355  0.48
2008 Feng Q, Sekula D, Guo Y, Liu X, Black CC, Galimberti F, Shah SJ, Sempere LF, Memoli V, Andersen JB, Hassel BA, Dragnev K, Dmitrovsky E. UBE1L causes lung cancer growth suppression by targeting cyclin D1. Molecular Cancer Therapeutics. 7: 3780-8. PMID 19074853 DOI: 10.1158/1535-7163.Mct-08-0753  0.56
2007 Freemantle SJ, Liu X, Feng Q, Galimberti F, Blumen S, Sekula D, Kitareewan S, Dragnev KH, Dmitrovsky E. Cyclin degradation for cancer therapy and chemoprevention. Journal of Cellular Biochemistry. 102: 869-77. PMID 17868090 DOI: 10.1002/Jcb.21519  0.56
Show low-probability matches.